News

Cardiovascular diseases are the leading cause of morbidity and mortality in the developed world, representing one of the biggest health care challenges. Controlling risk factors such as elevated blood pressure and cholesterol levels is one of the key issues in cardiovascular prevention.

Evidence shows that controlling atherosclerosis risk factors in people with clinically yet unmanifested signs correlates with a lower incidence of cardiovascular complications such as heart attack and stroke. Numerous studies performed on a large population sample have demonstrated that primary prevention has a bigger impact on reducing mortality than treating the disease itself. 

Between 19-21 April, Ljubljana was the venue for a EuroPrevent 2018 congress, the first professional event of its kind organised by the European Society of Cardiology held in Slovenia.  The Slovenian capital hosted more than 1,200 experts from around the world. The main theme of the congress centred on Evidence-based cardiovascular prevention: a lifelong endeavour.

At the congress we presented ourselves with an exhibit space and organised a satellite symposium that was attended by around 400 experts. At the symposium we discussed the challenges related to concomitant treatment of elevated blood pressure and cholesterol levels.

At Krka we are well aware of the significance of preventing cardiovascular events and the need for new treatment methods for patients with several risk factors. With the Prevent campaign we, along with other health care professionals, aim to raise awareness about the importance of controlling cardiovascular risk factors. We offer a wide range of medicines for treating elevated blood pressure and cholesterol levels, tailoring treatment to every patient's needs. Our latest solutions, fixed-dose combinations of an antihypertensive and a statin, allow us to push the boundaries of cardiovascular prevention. These fixed-dose combinations enable concomitant treatment of elevated blood pressure and cholesterol levels with just one tablet per day. We were the first European producer to launch a fixed-dose combination of rosuvastatin and amlodipine, followed by a fixed-dose combination of rosuvastatin and valsartan in 2018.